Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageLabcorp® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q1 2026 · $3.54BThe company’s own SEC segment disclosure.
- Diagnostics$2.76B78%
- Biopharma Laboratory Services$780.6M22%
Labcorp (LH) reported revenue of $3.54B in Q1 2026 (quarter ended March 31, 2026), up 5.8% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $278M (7.9% of revenue). For the full year FY2025, revenue was $14.0B (+7.2% year on year) and net income $877M. Its largest segment in 2026-Q1 was Diagnostics at $2.76B, 78% of the disclosed total, just ahead of Biopharma Laboratory Services at 22%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #22 of 29 by Smart Score